These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 33917727)

  • 1. Efficacy and Safety of Polyunsaturated Fatty Acids Supplementation in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents: A Systematic Review and Meta-Analysis of Clinical Trials.
    Händel MN; Rohde JF; Rimestad ML; Bandak E; Birkefoss K; Tendal B; Lemcke S; Callesen HE
    Nutrients; 2021 Apr; 13(4):. PubMed ID: 33917727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
    Gillies D; Leach MJ; Perez Algorta G
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007986. PubMed ID: 37058600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
    Gillies D; Sinn JKh; Lad SS; Leach MJ; Ross MJ
    Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD007986. PubMed ID: 22786509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate for children and adolescents with autism spectrum disorder.
    Sturman N; Deckx L; van Driel ML
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
    Storebø OJ; Ramstad E; Krogh HB; Nilausen TD; Skoog M; Holmskov M; Rosendal S; Groth C; Magnusson FL; Moreira-Maia CR; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009885. PubMed ID: 26599576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years.
    Storebø OJ; Elmose Andersen M; Skoog M; Joost Hansen S; Simonsen E; Pedersen N; Tendal B; Callesen HE; Faltinsen E; Gluud C
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD008223. PubMed ID: 31222721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylserine enriched with polyunsaturated n-3 fatty acid supplementation for attention-deficit hyperactivity disorder in children and adolescents with epilepsy: A randomized placebo-controlled trial.
    Rheims S; Herbillon V; Gaillard S; Mercier C; Villeuve N; Villéga F; Cances C; Castelnau P; Napuri S; de Saint-Martin A; Auvin S; Nguyen The Tich S; Berquin P; de Bellecize J; Milh M; Roy P; Arzimanoglou A; Bodennec J; Bezin L; Kassai B;
    Epilepsia Open; 2024 Apr; 9(2):582-591. PubMed ID: 38173190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supplementation with polyunsaturated fatty acids (PUFAs) in the management of attention deficit hyperactivity disorder (ADHD).
    Banaschewski T; Belsham B; Bloch MH; Ferrin M; Johnson M; Kustow J; Robinson S; Zuddas A
    Nutr Health; 2018 Dec; 24(4):279-284. PubMed ID: 29921155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 Polyunsaturated Fatty Acids for Core Symptoms of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Liu TH; Wu JY; Huang PY; Lai CC; Chang JP; Lin CH; Su KP
    J Clin Psychiatry; 2023 Aug; 84(5):. PubMed ID: 37656283
    [No Abstract]   [Full Text] [Related]  

  • 10. Which polyunsaturated fatty acids are active in children with attention-deficit hyperactivity disorder receiving PUFA supplementation? A fatty acid validated meta-regression analysis of randomized controlled trials.
    Puri BK; Martins JG
    Prostaglandins Leukot Essent Fatty Acids; 2014 May; 90(5):179-89. PubMed ID: 24560325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
    Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
    J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.
    Castells X; Blanco-Silvente L; Cunill R
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD007813. PubMed ID: 30091808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults.
    Lopez PL; Torrente FM; Ciapponi A; Lischinsky AG; Cetkovich-Bakmas M; Rojas JI; Romano M; Manes FF
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD010840. PubMed ID: 29566425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Cândido RCF; Menezes de Padua CA; Golder S; Junqueira DR
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013011. PubMed ID: 33460048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of polyunsaturated fatty acids in reducing child attention deficit and hyperactivity disorders.
    Transler C; Eilander A; Mitchell S; van de Meer N
    J Atten Disord; 2010 Nov; 14(3):232-46. PubMed ID: 20424008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Social skills training for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.
    Storebø OJ; Skoog M; Damm D; Thomsen PH; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD008223. PubMed ID: 22161422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Polyunsaturated Fatty Acids (PUFA) in the Treatment of Attention Deficit Hyperactivity Disorder.
    Assareh M; Davari Ashtiani R; Khademi M; Jazayeri S; Rai A; Nikoo M
    J Atten Disord; 2017 Jan; 21(1):78-85. PubMed ID: 23160488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit Hyperactivity Disorder: a Systematic Review and Meta-Analysis of Clinical Trials and Biological Studies.
    Chang JP; Su KP; Mondelli V; Pariante CM
    Neuropsychopharmacology; 2018 Feb; 43(3):534-545. PubMed ID: 28741625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of zinc supplementation in children with attention deficit hyperactivity disorder: A systematic review and dose-response meta‑analysis of randomized clinical trials.
    Talebi S; Miraghajani M; Ghavami A; Mohammadi H
    Crit Rev Food Sci Nutr; 2022; 62(32):9093-9102. PubMed ID: 34184967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.